Prentiss Smith & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Prentiss Smith & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,124	Closed	-$156K	–	250
2018 Q3	$156K	Buy	1,124 +9	+0.8%	+$1.13K	0.09%	65
2018 Q2	$138K	Sell	1,115 -1,359	-55%	-$159K	0.08%	72
2018 Q1	$276K	Buy	2,474 +2,465	+27,389%	+$295K	0.14%	68
2017 Q4	$1K	Hold	9	–	–	﹤0.01%	295
2017 Q3	$1K	Hold	9	–	–	﹤0.01%	240
2017 Q2	$1K	Sell	9 -391	-98%	-$45.5K	﹤0.01%	247
2017 Q1	$48K	Sell	400 -9	-2%	-$1.16K	0.03%	114
2016 Q4	$50K	Hold	409	–	–	0.03%	117
2016 Q3	$50K	Hold	409	–	–	0.03%	121
2016 Q2	$48K	Sell	409 -14	-3%	-$1.99K	0.03%	121
2016 Q1	$59K	Hold	423	–	–	0.03%	115
2015 Q4	$81K	Buy	423 +23	+6%	+$4.02K	0.04%	103
2015 Q3	$63K	Sell	400 -9	-2%	-$1.64K	0.03%	108
2015 Q2	$74K	Hold	409	–	–	0.04%	108
2015 Q1	$71K	Buy	409 +9	+2%	+$1.63K	0.03%	114
2014 Q4	$74K	Buy	400 +367	+1,112%	+$68K	0.03%	114
2014 Q3	$5K	Hold	33	–	–	﹤0.01%	211
2014 Q2	$5K	Hold	33	–	–	﹤0.01%	213
2014 Q1	$5K	Hold	33	–	–	﹤0.01%	226
2013 Q4	$4K	Buy	+33	New	+$3.96K	﹤0.01%	224

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prentiss Smith & Co's ALXN Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 1,124 shares — an estimated $156K sold.

Prentiss Smith & Co first reported a position in ALXN in Q4 2013 and held it in 20 quarters. The position peaked at $276K in Q1 2018. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Prentiss Smith & Co reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 1,124 Alexion Pharmaceuticals shares in Q4 2018, an estimated $156K.
Prentiss Smith & Co first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 20 quarters.
Prentiss Smith & Co's Alexion Pharmaceuticals position peaked at $276K in Q1 2018.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.